Min baggrund
Mette Thorn
Indehaver af STABIL.solutions
Min Baggrund
- PhD (Immunologi & Ernæring)
- Jeg har mangeårig erfaring fra forskning i livsstilssygdomme om sammenhænge mellem hjerne, tarm-, immun- og stofskiftesystem
- Jeg har mangeårig erfaring med kliniske studier og udvikling af validerede tests og analysepaneler
- Jeg brænder for at styrke helbred, trivsel og livskvalitet på individ- og virksomhedsniveau
- Jeg motiverer til realistiske livsstilsændringer, så der skabes overskud i hverdagen og større arbejdseffektivitet
Uddannelsesmæssig baggrund
2001
Ph.D., Department of Biochemistry and Nutrition, BioCenter – Technical University of Denmark
Ph.D. thesis: Effects of dietary oils on immunologic parameters – a study in man.
1997
Master of Science, Technical University of Denmark: Master thesis from the Department of Biochemistry and Nutrition, BioCenter.
Jeg har arbejdet med vaccine- og lægemiddeludvikling indenfor kræft, leddegigt, infektionssygdomme og inflammatoriske lidelser. Endvidere har jeg arbejdet med kliniske studier, CRO-services til pharma og biotech brancen samt udvikling af kosttilskud indenfor mave/tarm lidelser. Denne arbejdserfaring er opbygget gennem ansættelser hos Statens Serum Institutut, Novo Nordisk, Symphogen, Bioneer og Biocare i årene 2001-2017.
Jeg har desuden undervist samt har stor personlig interesse i kost og ernæring samt motion og disses indvirkning på helbredet. Jeg har en Ph.D grad fra Institut for Biokemi og Ernæring på DTU omhandlende fiskeolie-kosttilskuds effekter på immunsystemparametre. Planlægningen og gennemførelsen af flere kliniske studier inkluderende analyser i laboratoriet klæder mig på helt ned til det praktiske niveau ved helbredsundersøgelsens målinger af dit helbred i STABIL.solutions.
Publikationer
Ruzzi F, Palladini A, Clemmensen S, Strøbæk A, Buijs N, Domeyer T, Dorosz J, Soroka V, Grzadziela D, Rasmussen CJ, Nielsen IB, Soegaard M, Semprini MS, Scalambra L, Angelicola S, Landuzzi L, Lollini PL, Thorn M (2022). Prevention and therapy of metastatic HER-2+ mammary carcinoma with a human candidate HER-2 virus-like particle vaccine. Biomedicines 10, 2654.
Clausen C, Brown MH, Thorn M (2016). Immunology in a petri dish. BioZoom 2016 no. 1 – co-editor.
Thorn M (2016). Exploiting the diverse capabilities of in vitromonocyte-derived dendritic cells in the development of immunomodulatory drugs. BioZoom 2016 no. 1 – co-editor.
Atkinson SM, Bleil J, Maier R, Kühl A, Thorn M, Serikawa K, Fox B, Kruse K, Haase C, Skov S, Nansen, A, Syrbe U (2016). Anti-RANKL treatment inhibits erosive joint destruction and lowers inflammation but has no effect on bone formation in the delayed-type hypersensitivity arthritis (DTHA) model. Arthritis Research & Therapy 18:28.
Fomsgaard A, Karlsson I, Kløverpris H, Bonde J, Thorn M, Pedersen AE, Vinner L, Gram G, Svane IM, Gerstoft J, Kronborg G (2009). Peptide pulsed dendritic cells allows for induction of polyfunctional CD4+ T cell responses and help CD8+ T cell targeting subdominant CTL epitopes. Retrovirology 6:P311.
Kløverpris HN, Karlsson I, Thorn M, Buus S, Fomsgaard A (2009). Immune hierarchy among HIV-1 CD8+ T cell epitopes delivered by dendritic cells depends on MHC-I binding irrespective of mode of loading and immunization in HLA-A*0201 mice. APMIS 117, 849-55.
Kløverpris H, Karlsson I, Bonde J, Thorn M, Vinner L, Pedersen AE, Hentze J, Andresen BS, Svane IM, Gerstoft J, Kronborg G, Fomsgaard A (2009). Induction of Novel CD8+ T Cell Responses During Chronic Untreated HIV-1 Infection by Immunization with Subdominant CTL Epitopes. AIDS 23, 1329-40.
Schmidt EG, Buus S, Thorn M, Stryhn A, Leisner C, Claesson MH (2009). Peptide specific expansion of CD8(+) T cells by recombinant plate bound MHC/peptide complexes. J Immunol Methods 340, 25-32.
Thorn M, Wang M, Kløverpris H, Schmidt E, Fomsgaard A, Wenandy L, Berntsen A, Brunak S, Buus S, Claesson MH (2007). Identification of a new hTERT derived HLA-A2 restricted, naturally processed CTL epitope. Cancer Immunol Immunother 56, 1755-63.
Thorn M, Tang S, Therrien D, Kløverpris H, Vinner L, Kronborg G, Gerstoft J, Corbet S, Fomsgaard A (2007). Sequence conservation of subdominant HLA-A2-binding CTL epitopes in HIV-1 clinical isolates and CD8+T-lymphocyte cross-recognition may explain the immune reaction in infected individuals. APMIS 115, 757-68.
Gram GJ, Fomsgaard A, Thorn M, Madsen SM, Glenting J (2007). Immunological analysis of a Lactococcus lactis based DNA vaccine expressing HIV gp120.Genet Vaccines Ther 5, 3-13.
Wang M, Johansen B, Nissen MH, Thorn M, Kløverpris H, Fomsgaard A, Buus S, Claesson MH (2006). Identification of a HLA-A*0201 restricted Bcl2-derived epitope expressed on tumors. Cancer Lett. 251, 86-95.
Pedersen AE, Thorn M, Gad M, Walter MR, Johnsen HE, Gaarsdal E, Nikolajsen K, Buus S, Claesson MH, Svane IM (2005). Phenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination. Scan J Immunol 61, 147-56.
Forchhammer L, Thorn M, Met O, Gad M, Weidner MS, Claesson MH (2003). Immunobiological effects of glucosamine in vitro. Scan J Immunol 58, 404-11.
Andersen ML, Ruhwald M, Thorn M, Pedersen AE, Mathiassen S, Buus S, Claesson MH (2003). Tumor-associated antigens identified by mRNA expression profiling as tumor rejection epitopes. JIBTV 1, 1-9
Toft AD, Thorn M, Ostrowski K, Asp S, Møller K, Iversen S, Hermann C, Søndergaard SR, Pedersen BK (2000). N-3 polyunsaturated fatty acids do not affect cytokine response to strenuous exercise. J Appl Physiol 89, 2401-6.
Patenter
Nielsen LS, Jensen A, Pyke C, Jensen AMV, Koefoed K, Thorn M (2010). Method for cloning avian-derived antibodies. PCT WO 2010/022738 A1 (Int. pub. date: 4 March 2010).
Find os
Adresse:
Lejrvej 19, 1. sal
3500 Værløse